Original title: Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives
Bone is continually broken down and rebuilt, a process called remodeling. During this process, substances called bone biomarkers are released: some relate to bone formation, some to bone breakdown, and some regulate the process. Measuring these substances alongside bone mineral densityA measure of how much mineral is packed into bone. may give clinicians more information when assessing osteoporosis. The review discusses what the biomarkers do and newer ways to measure them, while noting that measurement remains a challenge.
Imagine keeping track of a house while workers repair it. A single check of the walls tells you how solid they are, but not whether parts are being rebuilt or worn away. In this paper, the house’s condition corresponds to bone mineral density, while clues released during repairs correspond to bone biomarkers; checking both may give a fuller picture of what is happening.
Osteoporosis affects bone strength, but measuring bone mineral density does not describe every part of bone remodeling. Bone biomarkers may add information for diagnosis and early assessment, although challenges in measuring them still need to be addressed.
The abstract does not report results from clinical trials or establish that these biomarkers improve diagnosis or treatment decisions. It identifies analytical approaches as a challenge and discusses the possibility of early assessment, rather than demonstrating its effectiveness.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives — Tsung‐Rong Kuo, Chih‐Hwa Chen — Biomarker Research — doi:10.1186/s40364-017-0097-4
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper.